Palmidrol
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Palmidrol
- Accession Number
- DB14043
- Description
A cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. Palmidrol is available for human use as a supplement (400 mg capsules) and as food for medical purposes In Italy and Spain (300 mg and 600 mg tablets).
- Type
- Small Molecule
- Groups
- Experimental, Nutraceutical
- Structure
Structure for Palmidrol (DB14043)
- Weight
- Average: 299.4919
Monoisotopic: 299.282429433 - Chemical Formula
- C18H37NO2
- Synonyms
- Hydroxyethylpalmitamide
- Monoethanolamine palmitic acid amide
- N-(2-Hydroxyethyl)palmitamide
- N-hexadecanoylethanolamine
- N-palmitoylethanolamine
- Palmidrol
- palmidrolum
- Palmitamide MEA
- Palmitic acid monoethanolamide
- Palmitinsaeure-beta-hydroxyethylamid
- Palmitoyl ethanolamide
- Palmitoyl-EA
- Palmitoylethanolamide
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAcebutolol The risk or severity of Tachycardia can be increased when Palmidrol is combined with Acebutolol. Acetazolamide The risk or severity of adverse effects can be increased when Palmidrol is combined with Acetazolamide. Acetophenazine The risk or severity of adverse effects can be increased when Palmidrol is combined with Acetophenazine. Aclidinium The risk or severity of Tachycardia and drowsiness can be increased when Aclidinium is combined with Palmidrol. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Palmidrol. Agomelatine The risk or severity of adverse effects can be increased when Palmidrol is combined with Agomelatine. Alfentanil The risk or severity of adverse effects can be increased when Palmidrol is combined with Alfentanil. Alimemazine The risk or severity of adverse effects can be increased when Palmidrol is combined with Alimemazine. Almotriptan The risk or severity of adverse effects can be increased when Palmidrol is combined with Almotriptan. Alosetron The risk or severity of adverse effects can be increased when Palmidrol is combined with Alosetron. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
- International/Other Brands
- Palmdrol prodes
Categories
- Drug Categories
- Agents producing tachycardia
- Alcohols
- Amines
- Amino Alcohols
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Infective Agents
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cannabinoids and similars
- Central Nervous System Agents
- Fatty Acids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Lipids
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Sensory System Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as carboximidic acids. These are organic acids with the general formula RC(=N)-OH (R=H, organic group).
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboximidic acids and derivatives
- Sub Class
- Carboximidic acids
- Direct Parent
- Carboximidic acids
- Alternative Parents
- Propargyl-type 1,3-dipolar organic compounds / Alkanolamines / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Alcohol / Aliphatic acyclic compound / Alkanolamine / Carboximidic acid / Hydrocarbon derivative / Organic 1,3-dipolar compound / Organic nitrogen compound / Organic oxygen compound / Organonitrogen compound / Organooxygen compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- N-(long-chain-acyl)ethanolamine, endocannabinoid, N-(saturated fatty acyl)ethanolamine (CHEBI:71464) / N-acyl ethanolamines (endocannabinoids) (LMFA08040013)
Chemical Identifiers
- UNII
- 6R8T1UDM3V
- CAS number
- 544-31-0
- InChI Key
- HXYVTAGFYLMHSO-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)
- IUPAC Name
- N-(2-hydroxyethyl)hexadecanamide
- SMILES
- CCCCCCCCCCCCCCCC(=O)NCCO
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0002100
- KEGG Drug
- D08328
- KEGG Compound
- C16512
- ChemSpider
- 4509
- BindingDB
- 29083
- 2001986
- ChEBI
- 71464
- ChEMBL
- CHEMBL417675
- ZINC
- ZINC000008035017
- Wikipedia
- Palmitoylethanolamide
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Pain, Chronic 1 2 Completed Treatment Gilles de la Tourette's Syndrome 1 2 Unknown Status Treatment Gilles de la Tourette's Syndrome 1 Not Available Completed Basic Science Amyotrophic Lateral Sclerosis (ALS) 1 Not Available Completed Treatment Chronic Pelvic Pain / Endometriosis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00136 mg/mL ALOGPS logP 5.74 ALOGPS logP 4.98 ChemAxon logS -5.3 ALOGPS pKa (Strongest Acidic) 15.46 ChemAxon pKa (Strongest Basic) -1.3 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 49.33 Å2 ChemAxon Rotatable Bond Count 16 ChemAxon Refractivity 90.09 m3·mol-1 ChemAxon Polarizability 40.05 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0w29-7179000000-22766d934944105dccf9 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-03dl-9130000000-c6d2bfc2e68da1f5b0d2 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-01ox-9410000000-d078025cabaaf62c59b9 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0002-1090000000-5224a67dd0daaea79191 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-01ot-5090000000-dd9396934201d60f5af2 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9010000000-d5bf936e945bfc965dfe
Drug created on May 22, 2018 11:59 / Updated on June 12, 2020 10:53
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates